

# Avi Orr-Urtreger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2062507/publications.pdf>

Version: 2024-02-01

168  
papers

8,309  
citations

41344

49  
h-index

56724

83  
g-index

171  
all docs

171  
docs citations

171  
times ranked

10069  
citing authors

#	ARTICLE	IF	CITATIONS
1	Glucocerebrosidase Activity is not Associated with Parkinson's Disease Risk or Severity. <i>Movement Disorders</i> , 2022, 37, 190-195.	3.9	19
2	Glucocerebrosidase Activity Is Not Associated with Parkinson's Disease Risk or Severity. <i>Movement Disorders</i> , 2022, 37, 651-652.	3.9	4
3	Aberrant dopamine transporter and functional connectivity patterns in LRRK2 and GBA mutation carriers. <i>Npj Parkinson's Disease</i> , 2022, 8, 20.	5.3	5
4	R869C mutation in molecular motor KIF17 gene is involved in dementia with Lewy bodies. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12143.	2.4	1
5	PARK16 locus: Differential effects of the non-coding rs823114 on Parkinson's disease risk, RNA expression, and DNA methylation. <i>Journal of Genetics and Genomics</i> , 2021, 48, 341-345.	3.9	4
6	The Effect of GBA Mutations and APOE Polymorphisms on Dementia with Lewy Bodies in Ashkenazi Jews. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 1221-1229.	2.6	12
7	The GBA-370Rec Parkinson's disease risk haplotype harbors a potentially pathogenic variant in the mitochondrial gene SLC25A44. <i>Molecular Genetics and Metabolism</i> , 2021, 133, 109-112.	1.1	2
8	Mutations in GBA and LRRK2 Are Not Associated with Increased Inflammatory Markers. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1285-1296.	2.8	16
9	C9orf72-G4C2 Intermediate Repeats and Parkinson's Disease; A Data-Driven Hypothesis. <i>Genes</i> , 2021, 12, 1210.	2.4	2
10	Biochemical markers for severity and risk in GBA and LRRK2 Parkinson's disease. <i>Journal of Neurology</i> , 2021, 268, 1517-1525.	3.6	4
11	Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): a cross-sectional study. <i>Lancet Neurology</i> , The, 2020, 19, 71-80.	10.2	94
12	Metabolic syndrome does not influence the phenotype of LRRK2 and GBA related Parkinson's disease. <i>Scientific Reports</i> , 2020, 10, 9329.	3.3	19
13	Clinical Observation: Effect of a Second Transpositioned Variant in a Family with Autosomal Dominant Ryanodine Receptor-1-Related Disease. <i>Journal of Pediatric Genetics</i> , 2020, 09, 121-124.	0.7	0
14	Tossing and Turning in Bed: Nocturnal Movements in Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 959-968.	3.9	34
15	A Possible Modifying Effect of the G2019S Mutation in the LRRK2 Gene on GBA Parkinson's Disease. <i>Movement Disorders</i> , 2020, 35, 1249-1253.	3.9	27
16	A novel mutation in <i>TARDBP</i> segregates with amyotrophic lateral sclerosis in a large family with early onset and fast progression. <i>Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration</i> , 2020, 21, 280-285.	1.7	0
17	Altered reward-related neural responses in non-manifesting carriers of the Parkinson disease related LRRK2 mutation. <i>Brain Imaging and Behavior</i> , 2019, 13, 1009-1020.	2.1	20
18	Revisiting the non-Gaucher-GBA-E326K carrier state: Is it sufficient to increase Parkinson's disease risk?. <i>Molecular Genetics and Metabolism</i> , 2019, 128, 470-475.	1.1	25

#	ARTICLE	IF	CITATIONS
19	Feasibility and safety of lumbar puncture in the Parkinson's disease research participants: Parkinson's Progression Marker Initiative (PPMI). <i>Parkinsonism and Related Disorders</i> , 2019, 62, 201-209.	2.2	15
20	Hierarchical Data-Driven Analysis of Clinical Symptoms Among Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 531.	2.4	13
21	Rare homozygosity in amyotrophic lateral sclerosis suggests the contribution of recessive variants to disease genetics. <i>Journal of the Neurological Sciences</i> , 2019, 402, 62-68.	0.6	10
22	The role of the nAChR subunits $\alpha 5$ , $\alpha 2$ , and $\alpha 4$ on synaptic transmission in the mouse superior cervical ganglion. <i>Physiological Reports</i> , 2019, 7, e14023.	1.7	8
23	Network abnormalities among non-manifesting Parkinson disease related LRRK2 mutation carriers. <i>Human Brain Mapping</i> , 2019, 40, 2546-2555.	3.6	16
24	Distinguishing Dementia With Lewy Bodies From Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 279-281.	1.3	2
25	High frequency of C9orf72 hexanucleotide repeat expansion in amyotrophic lateral sclerosis patients from two founder populations sharing the same risk haplotype. <i>Neurobiology of Aging</i> , 2018, 64, 160.e1-160.e7.	3.1	11
26	Progression in the LRRK2-Associated Parkinson Disease Population. <i>JAMA Neurology</i> , 2018, 75, 312.	9.0	109
27	Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma. <i>Nature Medicine</i> , 2018, 24, 1867-1876.	30.7	179
28	Survival rates among Parkinson's disease patients who carry mutations in the LRRK2 and GBA genes. <i>Movement Disorders</i> , 2018, 33, 1656-1660.	3.9	14
29	Parkinson's disease phenotype is influenced by the severity of the mutations in the GBA gene. <i>Parkinsonism and Related Disorders</i> , 2018, 55, 45-49.	2.2	90
30	Cerebral Imaging Markers of GBA and LRRK2 Related Parkinson's Disease and Their First-Degree Unaffected Relatives. <i>Brain Topography</i> , 2018, 31, 1029-1036.	1.8	23
31	A dose-effect of mutations in the GBA gene on Parkinson's disease phenotype. <i>Parkinsonism and Related Disorders</i> , 2017, 36, 47-51.	2.2	78
32	Two Ethnic Clusters with Huntington Disease in Israel: The Case of Mountain Jews and Karaites. <i>Neurodegenerative Diseases</i> , 2017, 17, 281-285.	1.4	3
33	Variable PARK2 Mutations Cause Early-Onset Parkinson's Disease in a Small Restricted Population. <i>Journal of Molecular Neuroscience</i> , 2017, 63, 216-222.	2.3	1
34	Estimation of genetic risk function with covariates in the presence of missing genotypes. <i>Statistics in Medicine</i> , 2017, 36, 3533-3546.	1.6	3
35	A cognitive fMRI study in non-manifesting LRRK2 and GBA carriers. <i>Brain Structure and Function</i> , 2017, 222, 1207-1218.	2.3	22
36	A Personalized Approach to Parkinson's Disease Patients Based on Founder Mutation Analysis. <i>Frontiers in Neurology</i> , 2016, 7, 71.	2.4	21

#	ARTICLE	IF	CITATIONS
37	SEPT14 Is Associated with a Reduced Risk for Parkinson's Disease and Expressed in Human Brain. <i>Journal of Molecular Neuroscience</i> , 2016, 59, 343-350.	2.3	13
38	High Frequency of <i>GBA</i> Gene Mutations in Dementia With Lewy Bodies Among Ashkenazi Jews. <i>JAMA Neurology</i> , 2016, 73, 1448.	9.0	48
39	Arm swing as a potential new prodromal marker of Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1527-1534.	3.9	136
40	Intact working memory in non-manifesting <i>LRRK2</i> carriers: an <i>fMRI</i> study. <i>European Journal of Neuroscience</i> , 2016, 43, 106-112.	2.6	16
41	A founder mutation in <i>ADAMTSL4</i> causes early-onset bilateral ectopia lentis among Jews of Bukharian origin. <i>Molecular Genetics and Metabolism</i> , 2016, 117, 38-41.	1.1	13
42	<i>OPTN</i> 691_692insAG is a founder mutation causing recessive ALS and increased risk in heterozygotes. <i>Neurology</i> , 2016, 86, 446-453.	1.1	37
43	Down-regulation of B cell-related genes in peripheral blood leukocytes of Parkinson's disease patients with and without <i>GBA</i> mutations. <i>Molecular Genetics and Metabolism</i> , 2016, 117, 179-185.	1.1	21
44	Higher Frequency of Certain Cancers in <i>LRRK2</i> G2019S Mutation Carriers With Parkinson Disease. <i>JAMA Neurology</i> , 2015, 72, 58.	9.0	76
45	<i>GBA</i> mutations are associated with Rapid Eye Movement Sleep Behavior Disorder. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 941-945.	3.7	117
46	Neuropsychological performance in <i>LRRK2</i> G2019S carriers with Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 106-110.	2.2	58
47	Interest in Genetic Testing in Ashkenazi Jewish Parkinson's Disease Patients and Their Unaffected Relatives. <i>Journal of Genetic Counseling</i> , 2015, 24, 238-246.	1.6	23
48	Age-specific penetrance of <i>LRRK2</i> G2019S in the Michael J. Fox Ashkenazi Jewish <i>LRRK2</i> Consortium. <i>Neurology</i> , 2015, 85, 89-95.	1.1	130
49	Differential effects of severe vs mild <i>GBA</i> mutations on Parkinson disease. <i>Neurology</i> , 2015, 84, 880-887.	1.1	277
50	<i>LRRK2</i> mutations in Parkinson disease; a sex effect or lack thereof? A meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 778-782.	2.2	30
51	Role of $\alpha 5$ -containing nicotinic receptors in neuropathic pain and response to nicotine. <i>Neuropharmacology</i> , 2015, 95, 37-49.	4.1	8
52	Genetic markers of Restless Legs Syndrome in Parkinson disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 582-585.	2.2	20
53	Nonmotor symptoms in healthy Ashkenazi Jewish carriers of the G2019S mutation in the <i>LRRK2</i> gene. <i>Movement Disorders</i> , 2015, 30, 981-986.	3.9	52
54	Efficient estimation of nonparametric genetic risk function with censored data. <i>Biometrika</i> , 2015, 102, 515-532.	2.4	5

#	ARTICLE	IF	CITATIONS
55	The emerging role of SMPD1 mutations in Parkinson's disease: Implications for future studies. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1294-1295.	2.2	33
56	Reorganization of corticostriatal circuits in healthy G2019S <i>LRRK2</i> carriers. <i>Neurology</i> , 2015, 84, 399-406.	1.1	66
57	Two novel mutations identified in familial cases with Donohue syndrome. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2014, 2, 64-72.	1.2	21
58	Michael J. Fox Foundation LRRK2 Consortium: geographical differences in returning genetic research data to study participants. <i>Genetics in Medicine</i> , 2014, 16, 644-645.	2.4	7
59	Variable Clinical Presentation of an MUC1 Mutation Causing Medullary Cystic Kidney Disease Type 1. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2014, 9, 527-535.	4.5	65
60	A voxel-based morphometry and diffusion tensor imaging analysis of asymptomatic Parkinson's disease-related G2019S LRRK2 mutation carriers. <i>Movement Disorders</i> , 2014, 29, 823-827.	3.9	20
61	Genome-wide mapping of IBD segments in an Ashkenazi PD cohort identifies associated haplotypes. <i>Human Molecular Genetics</i> , 2014, 23, 4693-4702.	2.9	49
62	Mechanism, Prevalence, and More Severe Neuropathy Phenotype of the Charcot-Marie-Tooth Type 1A Triplication. <i>American Journal of Human Genetics</i> , 2014, 94, 462-469.	6.2	42
63	CHRN3 c.-57A>G functional promoter change affects Parkinson's disease and smoking. <i>Neurobiology of Aging</i> , 2014, 35, 2179.e1-2179.e6.	3.1	10
64	Ethnic effect on FMR1 carrier rate and AGG repeat interruptions among Ashkenazi women. <i>Genetics in Medicine</i> , 2014, 16, 940-944.	2.4	12
65	Fall risk and gait in Parkinson's disease: The role of the LRRK2 G2019S mutation. <i>Movement Disorders</i> , 2013, 28, 1683-1690.	3.9	82
66	Parkinson disease phenotype in Ashkenazi jews with and without <i>LRRK2</i> G2019S mutations. <i>Movement Disorders</i> , 2013, 28, 1966-1971.	3.9	131
67	Neural correlates of executive functions in healthy G2019S LRRK2 mutation carriers. <i>Cortex</i> , 2013, 49, 2501-2511.	2.4	42
68	The p.L302P mutation in the lysosomal enzyme gene <i>SMPD1</i> is a risk factor for Parkinson disease. <i>Neurology</i> , 2013, 80, 1606-1610.	1.1	149
69	Single-channel properties of $\alpha 4$ , $\alpha 5$ and $\alpha 2$ nicotinic acetylcholine receptors in mice lacking specific nicotinic acetylcholine receptor subunits. <i>Journal of Physiology</i> , 2013, 591, 3271-3288.	2.9	14
70	A Genome-Wide Scan of Ashkenazi Jewish Crohn's Disease Suggests Novel Susceptibility Loci. <i>PLoS Genetics</i> , 2012, 8, e1002559.	3.5	144
71	Lower cognitive performance in healthy G2019S <i>LRRK2</i> mutation carriers. <i>Neurology</i> , 2012, 79, 1027-1032.	1.1	75
72	<i>HIF1A</i> C1772T polymorphism leads to HIF-1 $\alpha$ mRNA overexpression in prostate cancer patients. <i>Cancer Biology and Therapy</i> , 2012, 13, 720-726.	3.4	21

#	ARTICLE	IF	CITATIONS
73	Cerebral pathological and compensatory mechanisms in the premotor phase of leucine-rich repeat kinase 2 parkinsonism. <i>Brain</i> , 2012, 135, 3687-3698.	7.6	33
74	Association of Sequence Alterations in the Putative Promoter of <i>RAB7L1</i> With a Reduced Parkinson Disease Risk. <i>Archives of Neurology</i> , 2012, 69, 105.	4.5	52
75	Sperm Epidermal Growth Factor Receptor (EGFR) Mediates $\alpha 7$ Acetylcholine Receptor (AChR) Activation to Promote Fertilization. <i>Journal of Biological Chemistry</i> , 2012, 287, 22328-22340.	3.4	21
76	Undetected sex chromosome aneuploidy by chromosomal microarray. <i>Prenatal Diagnosis</i> , 2012, 32, 1117-1118.	2.3	5
77	A founder mutation causing a severe methylenetetrahydrofolate reductase (MTHFR) deficiency in Bukharian Jews. <i>Molecular Genetics and Metabolism</i> , 2012, 107, 608-610.	1.1	4
78	Tnfr $\alpha$ , Cox2 and AdipoQ adipokine gene expression levels are modulated in murine adipose tissues by both nicotine and nACh receptors containing the $\alpha 2$ subunit. <i>Molecular Genetics and Metabolism</i> , 2012, 107, 561-570.	1.1	12
79	Subunit composition of $\alpha 5$ containing nicotinic receptors in the rodent habenula. <i>Journal of Neurochemistry</i> , 2012, 121, 551-560.	3.9	22
80	The Age at Motor Symptoms Onset in LRRK2-Associated Parkinson's Disease is Affected by a Variation in the MAPT Locus: A Possible Interaction. <i>Journal of Molecular Neuroscience</i> , 2012, 46, 541-544.	2.3	25
81	Predictive value of TP53 fluorescence <i>in situ</i> hybridization in cytogenetic subgroups of acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2011, 52, 642-647.	1.3	6
82	Fighting the risk of developing Parkinson's disease; clinical counseling for first degree relatives of patients with Parkinson's disease. <i>Journal of the Neurological Sciences</i> , 2011, 310, 17-20.	0.6	15
83	Homozygosity for the MTX1 c.184T>A (p.S63T) alteration modifies the age of onset in GBA-associated Parkinson's disease. <i>Neurogenetics</i> , 2011, 12, 325-332.	1.4	15
84	The effects of aging vs. $\alpha 7$ nAChR subunit deficiency on the mouse brain transcriptome: aging beats the deficiency. <i>Age</i> , 2011, 33, 1-13.	3.0	6
85	Decreased expression of B cell related genes in leukocytes of women with Parkinson's disease. <i>Molecular Neurodegeneration</i> , 2011, 6, 66.	10.8	23
86	Gait alterations in healthy carriers of the LRRK2 G2019S mutation. <i>Annals of Neurology</i> , 2011, 69, 193-197.	5.3	140
87	$\alpha 4\beta 2$ nicotinic acetylcholine receptors in the early postnatal mouse superior cervical ganglion. <i>Developmental Neurobiology</i> , 2011, 71, 390-399.	3.0	10
88	Large-scale population screening for spinal muscular atrophy: Clinical implications. <i>Genetics in Medicine</i> , 2011, 13, 110-114.	2.4	36
89	Biochemical and functional properties of distinct nicotinic acetylcholine receptors in the superior cervical ganglion of mice with targeted deletions of nAChR subunit genes. <i>European Journal of Neuroscience</i> , 2010, 31, 978-993.	2.6	52
90	Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans. <i>Human Molecular Genetics</i> , 2010, 19, 1998-2004.	2.9	48

#	ARTICLE	IF	CITATIONS
91	False-positive results using a Gaucher diagnostic kit â€“ RecTL and N370S. <i>Molecular Genetics and Metabolism</i> , 2010, 100, 100-102.	1.1	9
92	Frequencies of C282Y and H63D alleles in the HFE gene among various Jewish ethnic groups in Israel: A change of concept required. <i>Genetics in Medicine</i> , 2010, 12, 122-125.	2.4	6
93	Activation of the Cholinergic Anti-Inflammatory System by Nicotine Attenuates Neuroinflammation via Suppression of Th1 and Th17 Responses. <i>Journal of Immunology</i> , 2009, 183, 6681-6688.	0.8	244
94	Dynamic modification strategy of the Israeli carrier screening protocol: inclusion of the Oriental Jewish Group to the cystic fibrosis panel. <i>Genetics in Medicine</i> , 2009, 11, 101-103.	2.4	5
95	Ashkenazi Parkinsonâ€™s disease patients with the LRRK2 G2019S mutation share a common founder dating from the second to fifth centuries. <i>Neurogenetics</i> , 2009, 10, 355-358.	1.4	23
96	The LRRK2 G2019S mutation as the cause of Parkinsonâ€™s disease in Ashkenazi Jews. <i>Journal of Neural Transmission</i> , 2009, 116, 1473-1482.	2.8	54
97	Being â€“at-riskâ€™ for developing cancer: cognitive representations and psychological outcomes. <i>Journal of Behavioral Medicine</i> , 2009, 32, 197-208.	2.1	27
98	Interspecies comparison of prostate cancer geneâ€™ expression profiles reveals genes associated with aggressive tumors. <i>Prostate</i> , 2009, 69, 1034-1044.	2.3	15
99	Genetic Testing in Israel: An Overview. <i>Annual Review of Genomics and Human Genetics</i> , 2009, 10, 175-192.	6.2	64
100	The Predictive Value of TP53 FISH Analysis for Treatment Response and Survival in Cytogenetic Subgroups of AML Patients.. <i>Blood</i> , 2009, 114, 2617-2617.	1.4	1
101	Mice Homozygous for the L250T Mutation in the Î±7 Nicotinic Acetylcholine Receptor Show Increased Neuronal Apoptosis and Die Within 1 Day of Birth. <i>Journal of Neurochemistry</i> , 2008, 74, 2154-2166.	3.9	118
102	Cytogenetic analysis of 101 skull base tumors. <i>Head and Neck</i> , 2008, 30, 567-581.	2.0	8
103	Advances in the genetics of Parkinson's disease. <i>Acta Pharmacologica Sinica</i> , 2008, 29, 21-34.	6.1	27
104	Differential brain transcriptome of Î±4 nAChR subunit-deficient mice: is it the effect of the null mutation or the background strain?. <i>Physiological Genomics</i> , 2007, 28, 213-222.	2.3	12
105	Expression changes in mouse brains following nicotine-induced seizures: the modulation of transcription factor networks. <i>Physiological Genomics</i> , 2007, 30, 242-252.	2.3	10
106	Carrier Screening for Gaucher Disease. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 1281.	7.4	68
107	Functional Analysis of the Aurora Kinase A Ile31 Allelic Variant in Human Prostate. <i>Neoplasia</i> , 2007, 9, 707-IN25.	5.3	29
108	<i>FGFR1</i> overâ€™ expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5â€™ CpG Island and abnormal expression of the <i>AKT1</i> , <i>NOG</i> , and <i>BMP4</i> genes. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 1028-1038.	2.8	57

#	ARTICLE	IF	CITATIONS
109	The homozygous P582S mutation in the oxygen-dependent degradation domain of HIF-1 $\alpha$ is associated with increased risk for prostate cancer. <i>Prostate</i> , 2007, 67, 8-13.	2.3	48
110	An Alternative SplicedRNASeqVariant in Peripheral Blood Leukocytes. <i>Journal of Interferon and Cytokine Research</i> , 2006, 26, 820-826.	1.2	5
111	Novel Genes Implicated in Embryonal, Alveolar, and Pleomorphic Rhabdomyosarcoma: A Cytogenetic and Molecular Analysis of Primary Tumors. <i>Neoplasia</i> , 2006, 8, 332-343.	5.3	53
112	Cytogenetic Analysis of Sinonasal Carcinomas. <i>Otolaryngology - Head and Neck Surgery</i> , 2006, 134, 654-660.	1.9	15
113	Mutation screening and association study of the candidate prostate cancer susceptibility genesMSR1,PTEN, andKLF6. <i>Prostate</i> , 2006, 66, 1052-1060.	2.3	25
114	Array-Based Comparative Genome Hybridization in Clinical Genetics. <i>Pediatric Research</i> , 2006, 60, 353-358.	2.3	26
115	<i>RNASeq</i> Mutation Screening and Association Study in Ashkenazi and Non-Ashkenazi Prostate Cancer Patients. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 474-479.	2.5	24
116	Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 3770-3774.	7.1	81
117	Increased severity of experimental colitis in alpha5 nicotinic acetylcholine receptor subunit-deficient mice. <i>NeuroReport</i> , 2005, 16, 1123-1127.	1.2	57
118	Selective deletion of the $\alpha 5$ subunit differentially affects somatic-dendriticversusaxonally targeted nicotinic ACh receptors in mouse. <i>Journal of Physiology</i> , 2005, 563, 119-137.	2.9	29
119	Initial experience of videocapsule endoscopy for diagnosing small-bowel tumors in patients with GI polyposis syndromes. <i>Gastrointestinal Endoscopy</i> , 2005, 62, 448-452.	1.0	36
120	Lower core body temperature and attenuated nicotine-induced hypothermic response in mice lacking the $\alpha 24$ neuronal nicotinic acetylcholine receptor subunit. <i>Brain Research Bulletin</i> , 2005, 66, 30-36.	3.0	31
121	Hidden function of neuronal nicotinic acetylcholine receptor $\alpha 2$ subunits in ganglionic transmission: comparison to $\alpha 5$ and $\alpha 24$ subunits. <i>Journal of the Neurological Sciences</i> , 2005, 228, 167-177.	0.6	8
122	Mice lacking neuronal nicotinic acetylcholine receptor $\alpha 24$ -subunit and mice lacking both $\alpha 5$ - and $\alpha 24$ -subunits are highly resistant to nicotine-induced seizures. <i>Physiological Genomics</i> , 2004, 17, 221-229.	2.3	76
123	A Comparison between Maternal Serum Free $\beta$ -Human Chorionic Gonadotrophin and Pregnancy-Associated Plasma Protein A Levels in First-Trimester Twin and Singleton Pregnancies. <i>Fetal Diagnosis and Therapy</i> , 2004, 19, 174-177.	1.4	14
124	Cytogenetic analysis of three variants of clival chordoma. <i>Cancer Genetics and Cytogenetics</i> , 2004, 154, 124-130.	1.0	25
125	Multiplex Nested PCR for Preimplantation Genetic Diagnosis of Spinal Muscular Atrophy. <i>Fetal Diagnosis and Therapy</i> , 2004, 19, 199-206.	1.4	26
126	Nicotinic acetylcholine receptor $\alpha 5$ subunits modulate oxotremorine-induced salivation and tremor. <i>Journal of the Neurological Sciences</i> , 2004, 222, 87-91.	0.6	10



#	ARTICLE	IF	CITATIONS
127	Synergistic control of keratinocyte adhesion through muscarinic and nicotinic acetylcholine receptor subtypes. <i>Experimental Cell Research</i> , 2004, 294, 534-549.	2.6	73
128	Combined cytogenetic and array-based comparative genomic hybridization analyses of Wilms tumors. <i>Cancer Genetics and Cytogenetics</i> , 2003, 141, 120-127.	1.0	13
129	Two novel translocations, t(2;4)(q35;q31) and t(X;12)(q22;q24), as the only karyotypic abnormalities in a malignant peripheral nerve sheath tumor of the skull base. <i>Cancer Genetics and Cytogenetics</i> , 2003, 145, 139-143.	1.0	13
130	The clinical application of spectral karyotyping (SKY?) in the analysis of prenatally diagnosed extra structurally abnormal chromosomes (ESACs). <i>Prenatal Diagnosis</i> , 2003, 23, 74-79.	2.3	15
131	Central Role of Fibroblast $\alpha 3$ Nicotinic Acetylcholine Receptor in Mediating Cutaneous Effects of Nicotine. <i>Laboratory Investigation</i> , 2003, 83, 207-225.	3.7	95
132	Functional role of $\alpha 7$ nicotinic receptor in physiological control of cutaneous homeostasis. <i>Life Sciences</i> , 2003, 72, 2063-2067.	4.3	41
133	Screening for Familial Dysautonomia in Israel: Evidence for Higher Carrier Rate among Polish Ashkenazi Jews. <i>Genetic Testing and Molecular Biomarkers</i> , 2003, 7, 139-142.	1.7	39
134	Deficiency of Nicotinic Acetylcholine Receptor $\alpha 4$ Subunit Causes Autonomic Cardiac and Intestinal Dysfunction. <i>Molecular Pharmacology</i> , 2003, 63, 574-580.	2.3	39
135	The Nicotinic Acetylcholine Receptor Subunit $\alpha 5$ Mediates Short-Term Effects of Nicotine in Vivo. <i>Molecular Pharmacology</i> , 2003, 63, 1059-1066.	2.3	182
136	Central role of $\alpha 7$ nicotinic receptor in differentiation of the stratified squamous epithelium. <i>Journal of Cell Biology</i> , 2002, 159, 325-336.	5.2	136
137	Rett Syndrome: Clinical Manifestations in Males With MECP2 Mutations. <i>Journal of Child Neurology</i> , 2002, 17, 20-24.	1.4	75
138	First Trimester Maternal Serum Free Human Chorionic Gonadotropin as a Predictor of Adverse Pregnancy Outcome. <i>Fetal Diagnosis and Therapy</i> , 2002, 17, 352-356.	1.4	67
139	Increased sensitivity to nicotine-induced seizures in mice heterozygous for the L250T mutation in the $\alpha 7$ nicotinic acetylcholine receptor. <i>NeuroReport</i> , 2002, 13, 191-196.	1.2	22
140	New Genetic Principles. <i>Clinical Obstetrics and Gynecology</i> , 2002, 45, 593-604.	1.1	5
141	Maternal serum HCG is higher in the presence of a female fetus as early as week 3 post-fertilization. <i>Human Reproduction</i> , 2002, 17, 485-489.	0.9	58
142	A Novel Founder Mutation in the RNASEL Gene, 471delAAAG, Is Associated with Prostate Cancer in Ashkenazi Jews. <i>American Journal of Human Genetics</i> , 2002, 71, 981-984.	6.2	113
143	The role of neuronal nicotinic acetylcholine receptor subunits in autonomic ganglia: lessons from knockout mice. <i>Progress in Neurobiology</i> , 2002, 68, 341-360.	5.7	72
144	Molecular analysis of the APC gene in 71 Israeli families: 17 novel mutations. <i>Human Mutation</i> , 2002, 19, 664-664.	2.5	35

#	ARTICLE	IF	CITATIONS
145	MECP2 Mutations in Israel: Implications for molecular analysis, genetic counseling, and prenatal diagnosis in Rett syndrome. <i>Human Mutation</i> , 2002, 20, 323-324.	2.5	31
146	Clinical and screening implications of the I1307K adenomatous polyposis coli gene variant in Israeli Ashkenazi Jews with familial colorectal neoplasia. <i>Cancer</i> , 2002, 94, 2561-2568.	4.1	33
147	Decreased first trimester PAPP-A is a predictor of adverse pregnancy outcome. <i>Prenatal Diagnosis</i> , 2002, 22, 778-782.	2.3	167
148	Autonomic function in mice lacking $\alpha 5$ neuronal nicotinic acetylcholine receptor subunit. <i>Journal of Physiology</i> , 2002, 542, 347-354.	2.9	73
149	Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. <i>Cancer Research</i> , 2002, 62, 6803-7.	0.9	106
150	Normal apoptosis levels in mice expressing one $\alpha 7$ nicotinic receptor null and one L250T mutant allele. <i>NeuroReport</i> , 2001, 12, 1643-1648.	1.2	13
151	First trimester PAPP-A in the detection of non-Down syndrome aneuploidy. <i>Prenatal Diagnosis</i> , 2001, 21, 547-549.	2.3	16
152	Effect of fetal gender on first trimester markers and on Down syndrome screening. <i>Prenatal Diagnosis</i> , 2001, 21, 1027-1030.	2.3	40
153	Novel mutations in the merin gene in Israeli families. <i>Human Mutation</i> , 2001, 17, 522-522.	2.5	6
154	Familial adenomatous polyposis at the Tel Aviv Medical Center: demographic and clinical features. <i>Familial Cancer</i> , 2001, 1, 75-82.	1.9	14
155	The Risk of Fragile X Premutation Expansion Is Lower in Carriers Detected by General Prenatal Screening Than in Carriers from Known Fragile X Families. <i>Genetic Testing and Molecular Biomarkers</i> , 2000, 4, 289-292.	1.7	28
156	Altered baroreflex responses in $\alpha 7$ deficient mice. <i>Behavioural Brain Research</i> , 2000, 113, 3-10.	2.2	66
157	Multiorgan Autonomic Dysfunction in Mice Lacking the $\alpha 2$ and the $\alpha 4$ Subunits of Neuronal Nicotinic Acetylcholine Receptors. <i>Journal of Neuroscience</i> , 1999, 19, 9298-9305.	3.6	263
158	Fetal muscle biopsy as a diagnostic tool in Duchenne muscular dystrophy. , 1999, 19, 921-926.		13
159	Prevalence of the I1307K APC gene variant in Israeli Jews of differing ethnic origin and risk for colorectal cancer. <i>Gastroenterology</i> , 1999, 116, 54-57.	1.3	78
160	The 8765delAG Mutation in BRCA2 Is Common among Jews of Yemenite Extraction. <i>American Journal of Human Genetics</i> , 1998, 63, 272-274.	6.2	32
161	High Frequency of a Common Bloom Syndrome Ashkenazi Mutation Among Jews of Polish Origin. <i>Genetic Testing and Molecular Biomarkers</i> , 1998, 2, 293-296.	1.7	45
162	$\alpha 7$ Nicotinic Receptor Subunits Are Not Necessary for Hippocampal-Dependent Learning or Sensorimotor Gating: A Behavioral Characterization of $\alpha 7$ -Deficient Mice. <i>Learning and Memory</i> , 1998, 5, 302-316.	1.3	271

#	ARTICLE	IF	CITATIONS
163	Mice Deficient in the $\alpha 7$ Neuronal Nicotinic Acetylcholine Receptor Lack $\alpha$ -Bungarotoxin Binding Sites and Hippocampal Fast Nicotinic Currents. <i>Journal of Neuroscience</i> , 1997, 17, 9165-9171.	3.6	478
164	Constitutional mosaicism for a chromosome 9 inversion resulting in recombinant aneusomy in an offspring. , 1997, 69, 360-364.		8
165	Segregation of a paternal insertional translocation results in partial 4q monosomy or 4q trisomy in two siblings. , 1996, 61, 10-15.		5
166	Analysis of the <i>Hoxd-3</i> Gene: Structure and Localization of Its Sense and Natural Antisense Transcripts. <i>DNA and Cell Biology</i> , 1995, 14, 295-304.	1.9	24
167	Cloning and mapping of the mouse $\alpha 7$ -neuronal nicotinic acetylcholine receptor. <i>Genomics</i> , 1995, 26, 399-402.	2.9	36
168	Developmental Localization of the Splicing Alternatives of Fibroblast Growth Factor Receptor-2 (FGFR2). <i>Developmental Biology</i> , 1993, 158, 475-486.	2.0	509